An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Trial Status: active
This is a randomised, multicentre, controlled, open-label, Phase III global study
comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd)
followed by AZD0120 versus standard induction regimens followed by continuous therapy
(IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are
ineligible for autologous stem cell transplant (ASCT) as initial therapy.
Inclusion Criteria
INCLUSION CRITERIA:
1. Participants must be 18 years or older, at the time of signing the ICF.
2. Participant must have documented diagnosis of MM according to the IMWG diagnostic
criteria.
3. Participant must have one or more of the following measurable disease criteria: (a)
Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum
immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa
lambda FLC ratio.
4. Participant must be deemed ineligible for ASCT while also having adequate organ
function for CAR-T cell treatment.
5. Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd)
as determined by the Investigator.
6. ECOG performance status Grade of 0 to 2.
7. Participant must have adequate organ and bone marrow function.
EXCLUSION CRITERIA:
1. Participant has active or prior CNS or meningeal involvement of MM.
2. Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating
plasma cells), Waldenström macroglobulinemia, or POEMS syndrome.
3. Participant has significant neurological or psychiatric condition posing risk or
impairing evaluation.
4. Participant has any other significant medical condition that increases unacceptable
risk, interferes with therapy delivery, or confounds evaluation.
5. Participant has a history of a prior non-haematologic malignancy unless the
participant has been disease-free with no evidence of recurrence for ≥ 2 years.
6. Participant has a history of haematologic malignancies, other than MM, regardless of
remission status.
7. Participant is positive for any of the following:
1. HIV: Known to be seropositive for HIV (including any history of HIV).
2. Chronic or active hepatitis B.
3. Active hepatitis C: Hepatitis C infection.
4. Additional local requirements for the testing for infectious diseases and
exclusions of applicable participants should be followed per local regulations.
8. Participant has clinically significant cardiovascular disease.
9. Participant has COPD with an FEV1 < 50% of predicted normal.
10. Additional exclusion for participants who are planned to receive IsaVRd as
induction: Participant has peripheral neuropathy Grade 4, Grade 3, Grade 2, or Grade
1 with pain.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07764978.
Locations matching your search criteria
United States
New York
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: Active
Name Not Available
Icahn School of Medicine at Mount Sinai
Status: Active
Name Not Available
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: Approved
Name Not Available
Texas
Houston
UT MD Anderson Cancer Center
Status: Approved
Name Not Available
The primary objective is to demonstrate the superiority of IsaVRd or DRd induction
followed by a single administration of AZD0120 compared to IsaVRd or DRd induction
followed by continuous IsaRd or DRd in terms of progression-free survival (PFS) according
to IMWG 2016 criteria, and as assessed by Blinded Independent Central Review (BICR) and